Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
1.
Acta cir. bras ; 32(6): 482-490, June 2017. tab
Article in English | LILACS | ID: biblio-886201

ABSTRACT

Abstract Purpose: To compare the effectiveness of anal and perianal condylomata treatment using argon plasma and electrofulguration. Methods: From January 2013 to April 2014, 37 patients with anal and perianal condylomata, who had been diagnosed through proctological examination, oncotic cytology, polymerase chain reaction (PCR) and histology, underwent treatment with argon plasma and electrofulguration. The perianal and anal regions were divided into two semicircles. Each semicircle was treated using one of the methods by means of simple randomization. Therapeutic sessions were repeated until all clinical signs of infection by HPV were eliminated. The patients were evaluated according to several variables like the genotype of HPV, HIV infection, oncological potential per genotype, oncotic cytology and histology. Results: Among all the variables studied, only immunosuppression due to HIV influenced the results, specifically when the fulguration method was used. There was no significant difference in effectiveness between argon and fulguration based on lesion relapse (p > 0.05). However, among HIV-positive patients, fulguration presented worse results, with a significant difference (p = 0.01). Conclusion: Regarding treatment of anal and perianal condylomata acuminata, comparison between applying fulguration and argon demonstrated that these methods were equivalent, but use of fulguration presented more relapses among HIV-positive patients.


Subject(s)
Humans , Male , Female , Adult , Argon/therapeutic use , Condylomata Acuminata/therapy , AIDS-Related Opportunistic Infections/therapy , Papillomavirus Infections/therapy , Electrocoagulation/methods , Plasma Gases/therapeutic use , Anal Canal/pathology , Anal Canal/virology , Condylomata Acuminata/virology , Prospective Studies
2.
Acta cir. bras ; 25(4): 322-327, July-Aug. 2010. graf
Article in English | LILACS | ID: lil-553237

ABSTRACT

PURPOSE: To evaluate the effectiveness of the use of the povidone-iodine (PVI) added to the liquid of wash of the peritoneal cavity in the reduction of bacterial absorption and in the remainder non-phagocyted bacteria in the circulating blood of rat. METHODS: Thirty four Wistar females rats were used, distributed in the following groups: A (n=10), non-treated; B (n=9), wash of the peritoneal cavity with solution of PVI to 1 percent in saline solution; C (n=15), wash of the cavity with saline solution. After anesthesia, it was made intraperitoneal infusion of solution of Escherichia coli labeled with 99mTc containing 10(8) CFU/ml. After 40 minutes, it was made the treatment, in the group A, manipulation of the viscera; in the group B, irrigation of the peritoneal cavity with warm solution of 1 percent PVPI to 37,5ºC, and in the group C irrigation with warm saline (37,5ºC). After 15 minutes of the treatment, blood samples and fragments of liver, spleen and lung was obtained for count of the radioactivity, and animals killed by abdominal aorta section. There were determined the bacterial absorption index and the remainder index in the bloodstream. RESULTS: Of the total of bacteria infused in the peritoneum, there was absorption of 0,92 percent (0,14 percent to 2,13 percent) in the animals of the group A (controls), 0,49 percent (0,18 percent to 0,71 percent) after use of topical PVPI (group B) and 0,80 percent (0,04 percent to 3,8 percent) after wash with saline solution (group C). There was significant reduction of the absorption when compared the treated animals with PVPI and the controls (p=0,003). Of the total of bacteria absorbed for the circulatory current, the percentile amount of bacteria non-phagocyted in the outlying blood was of 2,9 percent (1,1 percent to 17,7 percent) in the control group, 15,2 percent (8,3 percent to 21,4 percent) in those treated with PVPI (group B) and 6,9 percent (0,8 percent to 29,7 percent) after wash...


OBJETIVO: Avaliar a eficácia do uso do polivinilpirrolidona-iodo (PVPI) acrescido ao líquido de lavagem da cavidade peritoneal na redução da absorção bacteriana e no remanescente bacteriano não fagocitado no sangue periférico de ratos. MÉTODOS: Estudou-se 34 ratos Wistar fêmeas, distribuídos aleatoriamente nos seguintes grupos: controle (n=10), nenhum tratamento; PVPI (n=9), lavagem da cavidade peritoneal com solução de PVPI a 10 por cento em solução salina; salina (n=15), lavagem da cavidade com solução salina. Após anestesia, fez-se inoculação intraperitoneal de solução de Escherichia coli marcadas com 99mTc contendo 10(8) UFC/ml. Após 40 minutos, realizou-se o tratamento que foi, no grupo controle, manipulação das vísceras; no grupo PVPI, irrigação da cavidade peritoneal com solução de PVPI aquecido a 37,5ºC na concentração de 1 por cento, e no grupo salina irrigação com solução salina aquecida a 37,5ºC. Após 15 minutos do tratamento, os animais foram mortos por secção da aorta abdominal e colhidas amostras do sangue, do fígado, do baço e do pulmão para contagem da radioatividade. Foram determinados o índice de absorção bacteriano e o índice de remanescente no sangue periférico. RESULTADOS: Do total de bactérias inoculadas no peritôneo, houve absorção de 0,92 por cento (0,14 por cento a 2,13 por cento) nos animais do grupo controle, 0,49 por cento (0,18 por cento a 0,71 por cento) após uso do PVPI tópico e 0,80 por cento (0,04 por cento a 3,8 por cento) após lavagem com solução salina. Houve redução significativa da absorção quando comparados os animais tratados com o PVPI e os controles não tratados (p=0,03). Do total de bactérias absorvidas para a corrente circulatória, o percentual de bactérias não fagocitadas presentes no sangue periférico foi de 2,9 por cento (1,1 por cento a 17,7 por cento) nos animais controle 15,2 por cento (8,3 por cento a 21,4 por cento) naqueles tratados com PVPI e 6,9 por cento (0,8 por cento a 29,7 por...


Subject(s)
Animals , Female , Rats , Anti-Infective Agents, Local/therapeutic use , Escherichia coli Infections/drug therapy , Peritoneal Lavage , Peritonitis/drug therapy , Povidone-Iodine/therapeutic use , Disease Models, Animal , Drug Evaluation, Preclinical , Macrophages, Peritoneal , Peritoneal Cavity , Phagocytosis , Peritonitis/microbiology , Rats, Wistar , Solutions
SELECTION OF CITATIONS
SEARCH DETAIL